NCT06228846已完成1 期
An Open-Label Phase I Study to Evaluate the Safety,Tolerability and Preliminary Efficacy of YY001 in Patients with Advanced Solid Tumors
Shanghai Yuyao Biotech Co., Ltd.1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2022年7月14日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Dose limiting toxicity
研究概览
简要总结
The safety and tolerability of YY001 in the treatment of patients with advanced solid tumors were evaluated, and the possible dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II clinical dose (RP2D) were observed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Patients fully understand and sign ICF, voluntarily participate in the study, and able to follow and complete all study procedures.
- •Aged 18-75 years (including upper and lower limits), male or female.
- •Patients with histologically or cytologically confirmed advanced unresectable or metastatic solid tumors (mainly gastrointestinal tumors such as colorectal cancer and gastric cancer, and prostate cancer)
- •4.The standard treatment failure (disease progression after treatment or treatment side effects not tolerance), or top treatment, or shall not apply to the current standard treatment for patients
- •For patients with advanced solid tumors (dose-escalation phase), at least one tumor lesion that could be evaluated according to RECIST, version 1.1; (Dose-expansion phase) At least one measurable tumor lesion according to RECIST, version 1.1 (a tumor that is located in the previously irradiated area or another locoregional treatment site and is generally not considered a measurable lesion unless there is definite progression or persistence beyond 3 months of radiation);
- •ECOG physical condition≤1
- •Patients with advanced primary liver cancer should meet the Child-Pugh liver function grading: grade A and better grade B (≤7).
- •With adequate bone marrow, liver and kidney organ function:
- •Blood system within 14 days (not received blood transfusions or hematopoietic stimulating factor treatment): Absolute neutrophil count (ANC) ≥1.5×10^9/L; Platelet count (PLT) ≥75×10^9/L; Hemoglobin (Hb) ≥85g/L;
- •Liver function: Total bilirubin (TBIL) ≤1.5×ULN; Alanine aminotransferase (ALT) ≤3×ULN; Spread to the liver or liver cancer patient: 5 or less x ULN; Aspartate aminotransferase (AST) or less 3 x ULN; Spread to the liver or liver cancer patient: 5 or less x ULN;
- •Renal function: Creatinine (Cr) or less 1.5 x ULN; Creatinine clearance (Ccr) (calculated only when creatinine > 1.5× ULN) ≥50ml/min (calculated according to Cockcroft-Gault formula);
- •Blood coagulation function: Activated partial thromboplastin time (APTT) ≤1.5×ULN; International normalized ratio (INR) ≤1.5×ULN;
- •Urinary protein: Urine routine /24 hours urine protein qualitative ≤1+; Or urine protein qualitative ≥2+, 24 hours urine protein < 1g;
- •Expected survival of at least 3 months.
- •Women of childbearing potential had to have a negative serum or urine pregnancy test within 7 days before the first dose. Fertile male or female patients voluntarily during the study period and at the end of the study drug within 30 days of using effective birth control methods, such as abstinence, the double protective screen type cuts, condoms, contraceptive method of oral or injected contraceptives, intrauterine device, etc. All female patients will be considered fertile unless the female patient has undergone natural menopause, artificial menopause, or sterilization (e.g., hysterectomy, bilateral adnophorectomy, or radioactive ovarian irradiation).
排除标准
- •The adverse reactions of previous antineoplastic therapy have not recovered to CTCAE 5.0 grade ≤1 (except for toxicities without safety risks judged by investigators, such as alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stable with hormone replacement therapy);
- •Clinically symptomatic parenchymal or leptomeningeal metastases that were judged by the investigator to be ineligible for enrollment;
- •Within 4 weeks before delivery for the first time received chemotherapy, radiation therapy, biological therapy and endocrine therapy, immune therapy, such as antitumor drugs, with the exception of the following situations:
- •Nitrosourea or mitomycin C within 6 weeks before first use of study drug;
- •Oral fluorouracils and small-molecule targeted agents are administered 2 weeks before first use of the study drug or within the five half-lives of the drug, whichever is longer;
- •Have antitumor indications for the study of the first use of drugs of traditional Chinese medicines before 2 weeks;
- •Received other unlisted investigational drugs or treatments within 4 weeks before the first dose;
- •Previously received EP4 inhibitor (e.g. AN0025(E7046),LY3127760,ONO-4578) for anti-tumor treatment;
- •Major organ surgery (excluding needle biopsy) within 4 weeks before the first dose of medication or requiring elective surgery during the trial;
- •Uncontrolled malignant pleural, ascites, or pericardial effusion that was judged by the investigator to be ineligible for enrollment;
- •Unable to oral drug swallowing, or by the researchers determine the condition of the seriously affect the gastrointestinal tract absorption, including but not limited to, such as inflammatory bowel disease (crohn's disease and ulcerative colitis, for example), or malabsorption syndrome, or chronic diarrhea;
- •Patients who received a potent inducer or inhibitor of CYP3A4 within 1 week before the first dose or who required continued treatment with these drugs during the study;
- •10.Patients with active gastric and duodenal ulcer, ulcerative colitis and other gastrointestinal diseases, or unresected tumor with active bleeding, or other conditions that may cause gastrointestinal bleeding or perforation as judged by the investigator;
- •11.Thromboembolic events (including stroke events and/or transient ischemic attack) occurred within 12 months before the first dose of medication;
- •12.Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within 6 months before the first dose of medication; Congestive heart failure with New York Heart Association (NYHA) grade ≥2; Left ventricular ejection fraction (LVEF) <50%; A history of primary cardiomyopathy, clinically significant prolongation of the QTc interval, or a screening QTc interval >470ms in women and >450ms in men;
- •13.Patients with active or previous autoimmune diseases with potential recurrence (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), excluding patients with clinically stable autoimmune thyroid diseases and type I diabetes mellitus;
- •14.Prior immunotherapy with grade ≥3 irAE or grade ≥2 immune-related myocarditis;
- •15.Researchers to determine the clinical significance of 3 or more electrolyte abnormalities
- •16.Patients with active infection requiring antiinfective treatment or unexplained fever (body temperature >38.5 ° C) during screening or before the first dose of medication;
- •17.Patients with active pulmonary tuberculosis (TB) who were receiving anti-TB treatment or had received anti-TB treatment within 1 year before the first dose; Known human immunodeficiency virus (HIV) infection; Patients with a history of hepatitis B were in the stage of active infection (HBsAg positive and HBV-DNA > the detection limit of the research center); Patients with a history of hepatitis C were in the active infection stage, defined as positive HCV antibody test and detectable HCV RNA;
- •18.Women who are pregnant (positive pregnancy test within 14 days before medication) or are breastfeeding
- •19.Patients with known alcohol or drug dependence;
- •20.Patients judged by the investigator that may not be able to comply with all study procedures;
- •21.Any other disease, metabolic abnormality, abnormal physical examinations or laboratory abnormality with significant clinical significance. Investigator reasonably suspects that the patient has a disease or state that is not suitable for using of the study drug, or will affect interpretation of study results, or put the patient at high risk.
研究组 & 干预措施
Study treatment
Experimental
Method of Administration: Single dose period: Single oral ; Multiple dose period: Oral , QD.
干预措施: YY001 (Drug)
结局指标
主要结局
Dose limiting toxicity
时间窗: Up to 24 days after the initial drug administration
The incidence and severity of adverse events (TEAE) during treatment were graded according to the National Cancer Institute Standard for Common Terminology for Adverse Events (NCI-CTCAE, v5.0)
Maximum tolerated dose
时间窗: Up to 24 days after the initial drug administration
In the dose increment stage, the highest dose whose estimated DLT rate is closest to the target DLT rate but does not exceed the upper bound of the equivalent interval of DLT rate is selected as MTD.
Recommended Dose for Phase II Clinical Studies (RP2D)
时间窗: Up to 24 days after the initial drug administration
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of YY001.
次要结局
- Duration of Response(DoR)(Up to approximately 24 months)
- Overall Survival (OS)(Up to approximately 24 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid TumorsCancerNCT03131765Yisheng Biopharma (Singapore) Pte. Ltd.31
进行中（未招募）
1 期
A Study to Assess PV-10 Chemoablation of Cancer of the LiverCancer Metastatic to the LiverMetastatic MelanomaMetastatic Ocular MelanomaMetastatic Uveal MelanomaMetastatic Lung CancerMetastatic Colorectal CancerMetastatic Pancreatic CancerHepatocellular CarcinomaMetastatic Breast CancerMetastatic Colon CancerNCT00986661Provectus Biopharmaceuticals, Inc.78
招募中
1 期
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsHead and Neck CancerMalignant MelanomaColorectal CancerCervical CancerRenal Cell CarcinomaBreast CancerNCT06265025GeneMedicine Co., Ltd.125
招募中
1 期
A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04947033I-Mab Biopharma US Limited25
招募中
1 期
Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid TumorsSolid TumorNCT06132828Zhejiang Doer Biologics Co., Ltd.216